Nivolumab-Related Dry Mouth and Dry Eye: Cross-Sectional Study

Yıldırım, Özgen Ahmet; Poyraz, Kerem; Erdur, Erkan; Can, Canan; Gündoğan, Cihan; Güzel, Yunus; Etem, Hülya; Kömek, Halil

doi:10.1080/07357907.2021.1971241

Cited by 4 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result of the T-cell activation, immune checkpoint inhibitors are associated with multiple immune-related adverse events, one of which is immune checkpoint inhibitor-induced sicca syndrome. Exocrine gland damages leading to dry mouth and dry eyes were reported as adverse events following the use of nivolumab,[ 26 ] durvalumab,[ 27 ] and pembroliuzmab. [ 28 ] Rheumatic complications were well reported in the literature, especially with regard to the sicca symptoms.…”

Section: Resultsmentioning

confidence: 99%

A review on drug-induced dry eye disease

Kam

Zazzo²,

Gregorio³

et al. 2023

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

Dry eye disease encompasses a broad range of etiologies and disease subtypes which have similar clinical manifestations. Medications can cause dry eye disease or symptoms of dryness as a side effect by either interfering with the lacrimal gland or meibomian gland function, or both, and by other mechanisms that affect the ocular surface homeostasis. This is important to know and recognize as eliminating the offending medication can reverse the symptoms and, in many cases, prevent further deterioration of the ocular surface inflammation. This review focuses on drugs like systemic isotretinoin and taxanes, which cause meibomian gland dysfunction; immune checkpoint inhibitors that cause lacrimal gland dysfunction; gliptins and topical antiglaucoma medications that cause cicatrizing conjunctivitis; and epidermal growth factor receptor inhibitors, fibroblast growth factor receptor inhibitors, and belantamab mafodotin, which cause mucosal epitheliopathy. Many of these medications, particularly the newer anticancer agents, have only recently been introduced for clinical use, and knowledge and awareness of their ocular side effects are still evolving. This review aims to update ophthalmologists on the drug-induced causes of dry eye disease or symptoms of dryness, which is avoidable by discontinuation of the incriminating agent or can be mitigated by reducing the dose or frequency of usage.

show abstract

Section: Resultsmentioning

confidence: 99%

A review on drug-induced dry eye disease

Kam

Zazzo²,

Gregorio³

et al. 2023

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…The most common outcome measure used was the Clinical Oral Dryness Score (CODS) (colloquially known as the 'Challacombe Scale of Clinical Oral Dryness'), 77,78,85,105,213,218,255,278,353 followed by a physician carrying out a clinical evaluation to assess for multiple signs of dry mouth. 39,169,177,261,298,354,355 Other methods included scoring methods such as the Objective Oral Mucosa Scale (OOMS) 356 and a dichotomous objective dry mouth score. 353…”

Section: Domain 2: Salivary Biomarkersmentioning

confidence: 99%

“…381 Forty-four studies considered salivary gland hypofunction by scintigraphy. 134,157,170,225,268,283,293,320,355,376, Five studies used MRI as an outcome measure, 132,291,371,403,416 two used sialography, 371,424 and only a single paper assessed salivary gland hypofunction by CT. 425…”

Section: Domain 5: Imaging Modalities Assessing Salivary Gland Dysfun...mentioning

confidence: 99%